Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jiménez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martínez-López J, Wang Y, Link BK. Salles G, et al. Among authors: thieblemont c. Blood Adv. 2022 Nov 22;6(22):5835-5843. doi: 10.1182/bloodadvances.2022008150. Blood Adv. 2022. PMID: 35973192 Free PMC article. Clinical Trial.
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, Deconinck E, Haïoun C, Foussard C, Sebban C, Stamatoullas A, Milpied N, Boué F, Taillan B, Lederlin P, Najman A, Thièblemont C, Montestruc F, Mathieu-Boué A, Benzohra A, Solal-Céligny P. Colombat P, et al. Among authors: thieblemont c. Blood. 2001 Jan 1;97(1):101-6. doi: 10.1182/blood.v97.1.101. Blood. 2001. PMID: 11133748 Free article. Clinical Trial.
Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?
Traverse-Glehen A, Baseggio L, Bauchu EC, Morel D, Gazzo S, Ffrench M, Verney A, Rolland D, Thieblemont C, Magaud JP, Salles G, Coiffier B, Berger F, Felman P. Traverse-Glehen A, et al. Among authors: thieblemont c. Blood. 2008 Feb 15;111(4):2253-60. doi: 10.1182/blood-2007-07-098848. Epub 2007 Nov 27. Blood. 2008. PMID: 18042795 Free article.
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.
Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, Bieska G, Asikanius E, Carlile D, Birkett J, Pisa P, Cartron G. Salles G, et al. Among authors: thieblemont c. Blood. 2012 May 31;119(22):5126-32. doi: 10.1182/blood-2012-01-404368. Epub 2012 Mar 19. Blood. 2012. PMID: 22431570 Free article. Clinical Trial.
Splenic marginal zone lymphoma: current knowledge and future directions.
Thieblemont C, Davi F, Noguera ME, Brière J, Bertoni F, Zucca E, Traverse-Glehen A, Felman P, Berger F, Salles G, Coiffier B. Thieblemont C, et al. Oncology (Williston Park). 2012 Feb;26(2):194-202. Oncology (Williston Park). 2012. PMID: 22489356 Free article.
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
Delfau-Larue MH, Klapper W, Berger F, Jardin F, Briere J, Salles G, Casasnovas O, Feugier P, Haioun C, Ribrag V, Thieblemont C, Unterhalt M, Dreyling M, Macintyre E, Pott C, Hermine O, Hoster E; European Mantle Cell Lymphoma Network. Delfau-Larue MH, et al. Among authors: thieblemont c. Blood. 2015 Jul 30;126(5):604-11. doi: 10.1182/blood-2015-02-628792. Epub 2015 May 28. Blood. 2015. PMID: 26022239 Free article. Clinical Trial.
404 results